These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12494029)

  • 21. [Trimetazidine in correction of chronic heart failure in patients with ischemic heart disease].
    Nedoshivin AO; Kutuzova AE; Nesterova IV; Mikhaĭlova IE; Rubashkina EI; Novikova NA; Liasnikova EA; Perepech NB
    Kardiologiia; 2002; 42(3):12-5. PubMed ID: 12494179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of trimetazidine on atrial structural remodeling and platelet activation in dogs with atrial fibrillation.
    Han W; Li WM; Zhou HY; Huo H; Wei N; Dong G; Cao Y; Zhou G; Yang SS
    Chin Med J (Engl); 2009 Sep; 122(18):2180-3. PubMed ID: 19781307
    [No Abstract]   [Full Text] [Related]  

  • 23. Trimetazidine improves myocardial perfusion and left ventricular function in ischemic left ventricular dysfunction.
    Feola M; Biggi A; Francini A; Leonardi G; Ribichini F; Ferrero V; Uslenghi E
    Clin Nucl Med; 2004 Feb; 29(2):117-8. PubMed ID: 14734913
    [No Abstract]   [Full Text] [Related]  

  • 24. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
    Belardinelli R
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of trimetazidine plus sildenafil to chronic nitrates in the control of myocardial ischemia during sexual activity in patients with coronary artery disease.
    Rosano GM; Marazzi G; Patrizi R; Cerquetani E; Vitale C; Volterrani M; Fini M; Mercuro G
    Am J Cardiol; 2005 Feb; 95(3):327-31. PubMed ID: 15670539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic modulators for chronic cardiac ischemia.
    Parang P; Singh B; Arora R
    J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):217-23. PubMed ID: 16382258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation.
    Stanley WC; Sabbah HN
    Heart Fail Rev; 2005 Dec; 10(4):275-9. PubMed ID: 16583175
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effect of acetyl-CoA C-acyltransferase inhibitor trimetazidine on parameters of global and local systolic and diastolic functions of left ventricular myocardium in patients with combined postinfarction ischemic syndrome].
    Kastanaian AA; Nelasov NIu; Eroshenko OL; Kazarian NB; Drobotia NV
    Kardiologiia; 2003; 43(9):21-7. PubMed ID: 14593366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of trimetazidine in management of ischemic cardiomyopathy.
    Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC
    Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angina, myocardial hibernation and trimetazidine.
    Jackson G
    Int J Clin Pract; 1997 Sep; 51(6):347. PubMed ID: 9489058
    [No Abstract]   [Full Text] [Related]  

  • 31. [Coronary-ventricular sinusoid communications].
    Aispuru GR; Ugartemendia M; Páez Gill NE; Grimolizzi NS; Caminiti N
    Medicina (B Aires); 2009; 69(5):562. PubMed ID: 19897445
    [No Abstract]   [Full Text] [Related]  

  • 32. Cardioprotective effects of trimetazidine and a combination of succinic and malic acids in acute myocardial ischemia.
    Khazanov VA; Kiseliova AA; Vasiliev KY; Chernyschova GA
    Bull Exp Biol Med; 2008 Aug; 146(2):218-22. PubMed ID: 19145322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trimetazidine to reverse ischemia in patients with class I or II angina: a randomized, double-blind, placebo-controlled dobutamine-atropine stress echocardiography study.
    Cesar LA; Mathias W; Armaganijan D; Gimenez V; Jallad S; Del Monaco MI; Bicudo L; Meneguin S; Gomes EP; Brasil CK; Ramires JF
    Coron Artery Dis; 2007 Jun; 18(4):259-63. PubMed ID: 17496489
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential interest of anti-ischemic agents for limiting cyclosporin A nephrotoxicity.
    Simon N; Tillement JP; Albengres E; Jaber K; Hestin D; Roux F; Olivier P; d'Athis P; Kessler M; Berland Y; Crevat A
    Int J Clin Pharmacol Res; 1997; 17(4):133-42. PubMed ID: 9526174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease.
    Rehberger-Likozar A; Šebeštjen M
    Coron Artery Dis; 2015 Dec; 26(8):651-6. PubMed ID: 26049922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficiency of trimetazidine treatment of experimental ischemic heart disease in age aspect].
    Kukes VG; Zhernakova NI; Gorbach TV; Romashchenko OV; Rumbesht VV
    Eksp Klin Farmakol; 2013; 76(2):9-12. PubMed ID: 23631276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meeting the challenge of chronic ischaemic heart disease with trimetazidine.
    Marzilli M; Affinito S
    Coron Artery Dis; 2005 Nov; 16 Suppl 1():S23-7. PubMed ID: 16340400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapeutic application of myocardial cytoprotection].
    Ribeiro C
    Rev Port Cardiol; 1994 Sep; 13(9):669-70. PubMed ID: 7818940
    [No Abstract]   [Full Text] [Related]  

  • 39. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
    Lopaschuk GD; Barr R; Thomas PD; Dyck JR
    Circ Res; 2003 Aug; 93(3):e33-7. PubMed ID: 12869392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trimetazidine shortens QTc interval in patients with ischemic heart failure.
    Zemljic G; Bunc M; Vrtovec B
    J Cardiovasc Pharmacol Ther; 2010 Mar; 15(1):31-6. PubMed ID: 19966175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.